Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Public Health Dispatch: Pertussis in an Infant Adopted from Russia ---
May 2002
On May 2, 2002, the North Carolina Department of Health and Human Services notified CDC about an infant aged
10 months adopted from Russia who had culture-confirmed pertussis diagnosed. On April 8, the adoptive parents picked him
up in the orphan ward at hospital A in Bryansk and noticed that the child had upper respiratory congestion and cough.
The adoptive parents reported that the infant had not received any vaccinations and that another infant living in the same room
in hospital A had a severe cough. The adopted infant subsequently was examined by a local physician, who diagnosed
his condition as a "cold," and the infant was taken to the U.S. Embassy in Moscow, where the parents were interviewed for
an immigrant visa for the child.
On April 24, the infant and his parents traveled from Moscow to Raleigh, North Carolina, through New York
on commercial airline flights. On April 26, the infant was seen as an outpatient at a local clinic; a culture of a
nasopharyngeal swab confirmed infection with
Bordetella pertussis. The infant improved after treatment with clarithromycin and
was administered the first dose of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). The parents were
placed on azithromycin for prophylaxis.
CDC is collaborating with the U.S. Embassy, adoption agencies, visa applicant medical clinics in Moscow, and the
airline to identify and notify persons who might have been exposed to the infant during his communicable period. The airline
is working to identify those passengers who might have been exposed to the infant during his flights to North Carolina. CDC
is collaborating with state health departments, who are notifying and ensuring appropriate chemoprophylaxis and
vaccination for exposed passengers in their jurisdiction.
Health-care providers and public health officials are advised to consider pertussis when evaluating or notified of a
person with an acute illness characterized by cough with paroxysms, whoop, or post-tussive gagging or vomiting. Following are
CDC guidelines on the management of patients with pertussis and their contacts:
For symptomatic patients, test by culture of nasopharyngeal aspirate or swab; a nasopharyngeal
Dacron™ swab should be used. Swabs or aspirate should be placed in Regan Lowe transport media if direct inoculation of selective media is
not possible.
For hospitalized patients, respiratory isolation (droplet precautions) is recommended for at least the first 5 days
of antimicrobial treatment.
For symptomatic patients, the treatment of choice for pertussis is erythromycin for 14 days.
Trimethoprim-sulfamethoxozole is an alternative antibiotic. Limited clinical data suggest that newer macrolides, such as azithromycin
for 5--7 days or clarithromycin for 14 days, might be as effective as erythromycin in the treatment of pertussis and
are alternatives for patients who cannot tolerate erythromycin.
For exposed persons, chemoprophylaxis is recommended to limit secondary transmission. Exposure is defined as
having face-to-face contact, having direct contact with respiratory, oral, or nasal secretions, or being in the same room with
a coughing pertussis case-patient. The recommended chemoprophylaxis regimen is erythromycin for 14 days.
Alternative therapies are the same as for symptomatic patients.
Pertussis vaccination should be initiated or continued according to the recommended schedule for exposed children
aged <7 years who are undervaccinated or who have received <4 DTaP doses. Exposed children may receive DTaP dose 2 or
3 if 4 weeks have elapsed after dose 1 or 2, respectively. Children may receive DTaP dose 4 as early as age 12 months,
and preferably 6 months after dose 3. Children should be administered DTaP dose 5 unless a dose was given within the last 3
years or they are aged >7 years.
Reported by: L Johns, B Rowe-West, J MacCormack, MD, Div of Public Health, North Carolina Dept of Health and Human Svcs. D Kim,
MD, K Murray-Lillibridge, DVM, S Maloney, MD, J Barrow, M Cetron, MD, Div of Global Migration and Quarantine, National Center
for
Infectious Diseases; K Bisgard, DVM, T Tiwari, MD, Epidemiology and Surveillance Div, National Immunization Program; J Shah, MD,
C Ohuabunwo, MBBS, EIS Officers, CDC.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
